Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 2/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4955876 | 1.00 | LMNA (0.40) | LMNAPOLBSMN1; SMN2HTTCTSK | |
| SCHEMBL6135702 | 0.86 | L3MBTL1 (0.43) | — | |
| SCHEMBL6135738 | 0.86 | L3MBTL1 (0.43) | — | |
| SCHEMBL6135736 | 0.86 | L3MBTL1 (0.43) | — | |
| SCHEMBL6135705 | 0.86 | L3MBTL1 (0.43) | — | |
| SCHEMBL14282125 | 0.86 | CTSK (0.40) | CTSKCTSLCTSB | |
| SCHEMBL4954420 | 0.85 | LMNA (0.40) | LMNAALDH1A1 | |
| SCHEMBL4954423 | 0.85 | LMNA (0.40) | LMNAALDH1A1 | |
| SCHEMBL14282180 | 0.84 | PDF (0.51) | CTSKCTSLCTSB | |
| SCHEMBL6135528 | 0.84 | SIGMAR1 (0.37) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7323448-B2 | Antibacterial agents | BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) | 2008-01-29 | — | — | US | disclosed |
| US-7323448-B2 | Antibacterial agents | BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) | 2008-01-29 | — | — | US | disclosed |
| US-7323448-B2 | Antibacterial agents | BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) | 2008-01-29 | — | — | US | disclosed |
| US-7148198-B2 | Antibacterial agents | BRITISH BIOTECH PHARMACEUTICALS, LTD. (GB) | 2006-12-12 | — | — | US | disclosed |
| US-20060276409-A1 | Antibacterial agents | BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) | 2006-12-07 | — | — | US | disclosed |
| US-20050014702-A1 | Antibacterial agents | BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) | 2005-01-20 | — | — | US | disclosed |
| US-6787522-B2 | BACTERIAL POLYPEPTIDE DEFORMYLASE (PDF) INHIBITORS, N-FORMYL HYDROXYLAMINE DERIVATIVES | BRITISH BIOTECH PHARMACEUTICALS (GB) | 2004-09-07 | — | — | US | disclosed |
| EP-1052984-B1 | ANTIBACTERIAL AGENTS | VERNALIS OXFORD LTD (GB) | 2004-05-12 | — | — | EP | disclosed |
| US-20020165167-A1 | Antibacterial agents | BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) | 2002-11-07 | — | — | US | disclosed |
| US-6423690-B1 | Antibacterial agents | BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) | 2002-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276409-A1 | Antibacterial agents | CBR3, CBR1, SIGMAR1 | LMNA 1483/4885POLB 1160/4885SMN1; SMN2 3090/4885 |
| US-20050014702-A1 | Antibacterial agents | CBR3, CBR1, SIGMAR1 | LMNA 1483/4885POLB 1160/4885SMN1; SMN2 3090/4885 |
| US-20020165167-A1 | Antibacterial agents | CBR1, CBR3, SIGMAR1 | LMNA 578/4885POLB 1748/4885SMN1; SMN2 3034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.